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A
 
BSTRACT
 
Atopy is a common immune disorder characterized
by raised IgE levels, which lead to clinical disorders
(i.e. primarily bronchial asthma, atopic dermatitis and
allergic rhinoconjuctivitis). Interleukin (IL)-4 and IL-13,
derived from T-helper cell type 2 (Th2) subsets, are
central in mediating IgE production and development
of immediate hypersensitivity. Atopy is also character-
ized by Th1/Th2 skewing that derives from genetic and
environmental factors. The prevalence of atopy has
increased in recent decades, especially in developed
countries among children and young adults. In the
present review, we first discuss the relationship
between the Th1/Th2 imbalance and the recent rise of
allergy. Second, we present evidence that human
genetic variation is also a key factor responsible for
atopy.
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I
 
NTRODUCTION
 
Allergy is a multifactorial disease and there has been
little discussion regarding the mechanisms by which
identified genetic mutations interact with each other.
Atopic diseases were rare a few decades ago but, today,
constitute an increasingly severe public health problem.
 
1
 
The prevalence of atopic diseases in developed coun-
tries is estimated to exceed 30%.
 
2
 
 The genes that cause
atopic diseases must reside in the common human gene
repertoire; several environmental factors could cause the
overexpression of some constitutive genes, which would
then lead to the development of atopic diseases.
 
2
 
In the present review, we first discuss the reason why
the incidence of atopic diseases has increased recently.
Second, we introduce the present situation of genetic
analysis of atopy and asthma.
 
R
 
EDUCED
 
 
 
FREQUENCY
 
 
 
OF
 
 
 
BACTERIAL
 
 
 
AND
VIRAL
 
 
 
INFECTIONS
 
Viral infections generally induce a strong cell-mediated
immune response; an immune response that is mainly
driven by T helper 1 (Th1) cells and interferon (IFN)-
 
γ
 
.
Intracellular bacteria, such as mycobacteria, have the
same ability: therefore, it has been assumed that early
infections with, in particular, 
 
Mycobacterium tuberculosis
 
could protect against the development of allergic dis-
eases in later life.
 
1
 
 Our study
 
3
 
 supports this assumption.
From a population of approximately 1000 12–13-year-
old schoolchildren attending the 18 junior high schools
in Wakayama Prefecture, Southern Honshu, Japan, in
1995, we studied 867 children by complete retro-
spective examination of the records of their tuberculin
responses.
 
3
 
 The children responded to a questionnaire
documenting atopic symptoms and social and environ-
mental variables and we measured IgE serum levels, as
well as Th1 and Th2 cytokine profiles.
 
4
 
 These data were
analyzed in relation to the record of tuberculin res-
ponses.
 
3
 
 A strong inverse association was found between
positive tuberculin responses at both 6 and 12 years of
age and a range of atopic characteristics, including
allergic symptoms at any age and IgE levels, and Th2
cytokine profiles assayed at 12 years of age (Tables 1,2).
 
3
 
Asthmatic symptoms were one-half to one-third as likely
in positive tuberculin responders as in negative respon-
ders (Table 2).
 
3
 
 Moreover, remission of atopic symptoms
between 7 and 12 years of age was six- to ninefold as
likely as in positive tuberculin responders. Serum IgE
levels, both total and allergen specific, were also lower
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Table 1
 
History of infectious diseases, atopic symptoms, IgE levels and cytokine profiles in subjects grouped according to
tuberculin reactivity
Measurement
Group 1
(
 
n
 
 = 290)
Group 2
(
 
n
 
 = 289)
Group 3
(
 
n
 
 = 213)
Group 4
(
 
n
 
 = 75)
Total
(
 
n
 
 = 867)
Tuberculin response
At 6 years of age – – + +
At 12 years of age – + + –
Positive antiviral immunity (%)
Measles (history + vaccine) 83.4 87.2 84.5 81.3 84.3
Chicken pox (history + vaccine) 86.9 82.3 82.2 82.7 83.9
Mumps (history + vaccine) 62.8 60.9 60.1 57.3 61.0
No. subjects with IgE to 
 
Ascaris
 
2 2 2 1 7
Symptoms (%)
Atopy (past + present) 46.8 33.9
 
‡‡
 
25.8
 
‡‡
 
38.7 36.6
Atopy (present) 32.1 7.9
 
‡‡‡
 
9.8
 
‡‡‡
 
30.7 18.5
Asthma (past + present) 13.4 4.1
 
‡‡
 
3.7
 
‡‡
 
6.8 7.4
Rhinitis (past + present) 16.2 4.8
 
‡‡
 
8.6
 
‡
 
14.6 10.4
Eczema (past + present) 22.7 12.8
 
‡‡
 
12.2
 
‡‡
 
16.0 16.2
Geometric mean IgE (IU/mL) 208      149**        98*** 178 154
Positive ASE (%) 55.8 43.9
 
‡‡
 
41.8
 
‡‡
 
53.3 48.2
Atopic (high IgE or positive ASE; %) 65.5 54.0
 
‡‡
 
49.2
 
‡‡
 
61.3 57.3
Median cytokine level (pg/mL)
IL-4 1.88 0.96
 
†
 
0.92
 
†
 
1.66 1.22 (10.2–UD)
IL-13 18.3 10.2
 
†††
 
7.8
 
†††
 
19.1 14.2 (45.6–UD)
IL-10 5.9 3.1
 
††
 
2.9
 
††
 
5.9 3.9 (10.2–UD)
IL-12 UD UD UD UD UD
IFN
 
γ
 
7.8 11.0
 
††
 
13.2
 
††
 
6.4 10.5 (23.2–UD)
Positive family history within three
generations (%)
54.1 49.8 49.8 48.0 51.0
Mean BMI (kg/m
 
2
 
) 21.1 22.0 21.9 21.2 21.6
 
Data in parentheses show the maximum–minimum values.
**
 
P
 
 < 0.01, ***
 
P
 
 < 0.001 compared with group 1 (Student’s 
 
t
 
-test); 
 
†
 
P
 
 < 0.05, 
 
††
 
P
 
 < 0.01, 
 
†††
 
P
 
 < 0.001 compared with group 1 (median
test); 
 
‡
 
P
 
 < 0.05, 
 
‡‡
 
P
 
 < 0.01, 
 
‡‡‡
 
P
 
 < 0.001 compared with group 1 (
 
χ
 
2
 
-test).
ASE, allergen-specific IgE; IL, interleukin; IFN, interferon; BMI, body mass index; UD, undetectable.
 
Table 2
 
Odds ratios for atopy and for the occurrence and remission of atopic symptoms in positive compared with negative
tuberculin responders according to age
Tuberculin response Odds ratio 
Atopy Atopic symptoms 
Occurrence Remission
Conversion to positive up to 6 years 0.50 (0.29–0.83)* Asthma: 0.31 (0.22–0.45)* Asthma: 8.2 (6.0–9.8)**
of age Eczema: 0.50 (0.33–0.91)* Eczema: 1.6 (1.0–2.2)*
Conversion to positive between 6 and 
12 years of age
0.43 (0.25–0.83)** Asthma: 0.42 (0.24–0.56)* Asthma: 6.0 (2.8–10.3)***
Eczema: 6.7 (4.8–11.4)***
Rhinitis: 9.0 (6.2–14.2)***
 
Multiple logistic analysis was conducted with the SPSSX package, version 2.2 (SPSS Inc., Chicago, IL, USA).
In all models, allowance was made for dichotomized variables, including sex, lifestyle, nutritional status, environmental factors and family
history. Only significant values are shown (*
 
P
 
 < 0.05, **
 
P
 
 < 0.01, ***
 
P
 
 < 0.005 compared with negative conversion of tuberculin response).
Figures in parentheses are the 95% confidence intervals.
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in positive tuberculin responders.
 
3
 
 A plot of the loga-
rithm of total serum IgE against the diameter of tuber-
culin response showed an inverse linear relationship,
with 
 
r
 
 = –0.492.
 
3
 
 A strong inverse association between
delayed hypersensitivity to 
 
M. tuberculosis
 
 and atopy was
observed;
 
3
 
 positive tuberculin responses predicted a
lower incidence of asthma, lower serum IgE levels and
cytokine profiles biased towards the Th1 type.
 
3
 
 It is
suggested that exposure and response to 
 
M. tuberculosis
 
may, by modification of immune profiles, inhibit atopic
disorders.
 
3
 
In addition to 
 
M. tuberculosis,
 
 an inverse relationship
between the prevalence of atopy and a single virus, such
as the hepatitis A virus, has been observed.
 
5
 
 Because
infection with the hepatitis A virus is a strong marker of
poor hygiene,
 
6
 
 the association between poor hygiene
and protection against atopy is clear.
 
7
 
Although we found no relationship between a history
of measles infection and atopy in our study, epidemio-
logical data from Guinea-Bissau show that a history of
childhood measles infection around the time of an epi-
demic was associated with a one-half reduction in the
rate of positive atopic skin tests.
 
8
 
 It is likely that a set of
specific infections that strongly promote Th1 immunity
have the potential to inhibit atopic disorders by repres-
sion of Th2 immunity.
 
3
 
T
 
HE
 
 T
 
H
 
1/T
 
H
 
2 
 
IMBALANCE
 
Atopic allergy is characteristically associated with an
imbalance between various types of T cells and, con-
sequently, an increased synthesis of IgE.
 
1
 
 Early studies
revealed a T cell imbalance that was found to be present
in all the important types of childhood atopic diseases,
such as bronchial asthma, hay fever and atopic derma-
titis.
 
9
 
 In 1986, Mosmann 
 
et al.
 
 reported that most cloned
lines of murine CD4
 
+
 
 T cells could be classified into
two groups, Th1 and Th2, based on the cytokines they
produced and their related functional activities.
 
10
 
 The
Th1 cells are now defined by their production of inter-
leukin (IL)-2 and IFN-
 
γ
 
 and the Th2 cells are defined by
their production of IL-4, IL-5, IL-6, IL-10 and IL-13; both
cell types produce IL-3, tumor necrosis factor (TNF)-
 
α
 
and granulocyte–macrophage colony stimulating factor
(GM-CSF).
 
2
 
 Atopic diseases are characterized by an
imbalance between these cytokines, so that type 2
cytokines are provided in abnormally high concentra-
tions relative to the type 1 cytokines.
 
1
 
 The Th2 cells also
induce the local influx of eosinophils, which release toxic
products that contribute to tissue damage.
 
11
 
 In addition,
the Th2 cell releases key cytokines, particularly IL-4,
which are essential for the maturation of CD4
 
+
 
 naïve
T cells towards Th2 cells and the production of IgE,
 
12,13
 
and IL-5, which regulates activation and tissue recruit-
ment of eosinophils.
 
14
 
 This is known as the ‘Th2 hypo-
thesis in allergy’.
 
11
 
 Among the factors that control the
differentiation of T lymphocytes, IFN-
 
γ
 
 plays pivotal roles
in promoting the differentiation of CD4
 
+
 
 naïve T lym-
phocytes towards Th1 effector cells.
 
15
 
 The Th1 and Th2
subsets are subject to cross-regulation, such that Th2
development is inhibited by IFN-
 
γ
 
, whereas Th1 develop-
ment is inhibited by IL-4.
 
15
 
 An imbalance between IL-4
and IFN-
 
γ
 
 may lead to an abnormally high production of
IgE and of the various mediators that give rise to allergic
symptoms.1 The reliable predictive marker for atopic
disease known today is perhaps a decreased ability of
cord-blood lymphocytes to produce IFN-γ.1 A reduced
ability to produce IFN-γ in the neonatal period has been
shown to be closely correlated with an increased
tendency to develop allergic sensitization and atopic
diseases in later life.16–18
DOMINANT EFFECT OF THE ILE50VAL VARIANT 
OF THE HUMAN IL4 RECEPTOR α-CHAIN IN IGE 
SYNTHESIS
Interleukin-4 is a pleiotropic cytokine that plays a crucial
role in IgE-dependent atopic disorders;19 it is central to
B cells switching to IgE antibody production. Human
IL-4 operates through the IL-4 receptor (IL-4R) and,
thereby, activation of STAT6 (signal transducer and
activator of transcription 6).20 An Ile50Val (numbering
for mature peptide) variant that is the extracellular
variant of human IL-4R21 has been identified.22,23 To test
whether the Ile50Val variant promotes dysregulation of
IgE synthesis, we first conducted a genetic association
study for serum IgE levels in a Japanese population.24
There was a significant difference in Ile/Val 50 genotype
frequencies between control and atopic subjects; Ile50
was associated with atopic asthma, but not with non-
atopic asthma; Ile50 was specifically and significantly
associated with raised total serum IgE levels and mite-
specific IgE.24 The association with atopy was especially
strong in children.24 The high frequency of Ile50 hom-
ozygotes (approximately 60%) in the childhood atopic
asthma group described here and the significant skewing
from Hardy–Weinberg equilibrium (P < 0.0001) suggest
a largely recessive genetic effect for Ile50 on atopy.24
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Second, we investigated the relative activation of the
transcription factor STAT6.24 The Ile50 variant aug-
mented STAT6 activation 1.8-fold compared with the
Val50 variant in both mouse (BF-GETP) and human
(J-GETP) B cell lines.24 Therefore, these data from both
the mouse and human cell lines strongly suggest that the
Ile50 variant of IL-4R significantly upregulates receptor
response to IL-4, with a resultant increase in the activa-
tion of STAT6 and, hence, increased cell proliferation
and increased IgE production.24 In contrast, another
variant of human IL-4Rα carrying arginine (Arg) at 551
(numbering from the start of the mature protein) instead
of glutamine (Gln) has also been identified and shown to
be correlated with hyper-IgE syndrome and severe atopic
eczema and to cause upregulation of CD23 expression
and dissociation with the tyrosine phosphatase SHP-1.25
Based on these studies, two possibilities arise. One is that
these two substitutions act independently to cause atopy.
In this case, an individual bearing both variants would
belong to a higher-risk group than an individual who
carries each single variant. The other possibility is that
these two polymorphisms are in linkage disequilibrium.
In this case, either of these variants simply represents a
marker of the other variant. It is important to address this
point in order to estimate the quantity of risk of contract-
ing atopic asthma.26 We analyzed responsiveness to IL-4
of transfectants with four kinds of IL-4Rα carrying either
Val or Ile at 50 and either Gln or Arg at 551.26 The
substitution of Ile for Val augmented STAT6 activation,
proliferation and transcription activity of the Iε promoter
by IL-4, whereas substitution of Arg for Gln did not
change these IL-4 signals. Arg551 was not associated
with atopic asthma in the Japanese population.26 Taken
together, substitution of Arg551 does not enhance the
IL-4 signal for generation of germline transcript, whereas
the substitution of Ile50 contributes to enhancement of
IgE synthesis.26
GENETIC VARIANTS OF IL-13 SIGNALING AND 
ASTHMA AND ATOPY
Atopy is a key predisposition to bronchial asthma
between the ages of 3 and 20 years.12,27 Bronchial
hyper-responsiveness (BHR), an exaggerated broncho-
spastic response to specific and non-specific substances,
represents a physiological hallmark of asthma induced
by Th2 cytokines such as IL-4, -5, -9, -10 and -13.12,27
Recent animal model data suggest that IL-13 is a central
cytokine in promoting asthma, through the stimulation of
bronchial epithelial mucus secretion and smooth muscle
hyper-reactivity.28 Interleukin-13 is a 12 kDa protein
product and shares several biological profiles with
IL-4,12,27 including IgE production, CD23 and major
histocompatibility complex (MHC) class II expression,
inhibition of antibody dependent cell-mediated cytotox-
icity with downregulation of IgG type I receptor (FcγRI),
and suppression of type I IFN. Although IL-4 and IL-13
possess many similar biological activities,12,27 IL-13 shows
some unique activities. Unlike IL-4-deficient mice, IL-13-
null mice fail to generate goblet cells, responsible for
mucus overproduction in asthma, fail to recover basic
IgE levels after stimulation with IL-4 and fail to expel
helminths.29 Interleukin-13 operates through IL-13R,
a heterodimer of IL-4Rα and IL-13Rα1 chains.12,13,27
Interleukin-13 is crucial for allergen-induced BHR in
experimental animals and may be relevant to human
asthma.30,31 Significantly higher IL-13 levels have been
found in asthmatic patients with and without atopy.32,33
A novel variant of human IL-13, Gln110Arg, on
chromosome 5q31 was found to be associated with
asthma rather than IgE levels in case-control populations
from Britain and Japan (peak odds ratio (OR) = 2.31,
95% confidence interval (CI) 1.33–4.00); the variant
also predicted asthma and higher serum IL-13 levels in
a general Japanese pediatric population.28 Immunohis-
tochemistry demonstrated that both subunits of IL-13R
are prominently expressed in bronchial epithelium and
smooth muscle from asthmatic subjects.28 Detailed mole-
cular modeling analyses indicate that residue 110 of
IL-13, the site of the charge-modifying variants Arg and
Gln, is important in the internal constitution of the
ligand and crucial in ligand–receptor interaction.28 A
non-coding variant of IL-13Rα1, namely A1398G, on
chromosome Xq13 was found to be associated primarily
with high IgE levels (OR = 3.38 in males, 1.10 in
females) rather than asthma.28 Thus, certain variants of
IL-13 signaling are likely to be important promoters
of human asthma.
CHROMOSOME 11q13, FCεRIβ AND ATOPIC 
ASTHMA
The first genetic region reported to show linkage to
atopy was chromosome 11q13.34,35 The evidence for
genetic linkage was confounded by the existence of a
maternal pattern of inheritance.35,36 A significant portion
of atopic asthmatic families in Caucasian and Japanese
populations may be linked to chromosome 11q13
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through the maternal line.35,36 The β-subunit of the high-
affinity IgE receptor (FcεRIβ) gene has been mapped to
chromosome 11q13.137–41 and is a candidate gene for
atopy because of its important role in initiating a type I
allergic reaction by mast cells and basophils.42 A recent
large-scale population-based linkage study by sib-pair
methodology in an Australian population affirms linkage
of asthma with microsatellite repeats of FcεRIβ, but not
with other markers on 11q13.43
The FcεRIβ gene is composed of seven exons and six
introns, spanning approximately 11 kb.44 Eight variants
of this gene have been identified, including three coding
and five non-coding variants; three coding polymor-
phisms within the FCERB1 are Ile181Leu, Val183Leu45–47
and Glu237Gly.48,49 A strong association was seen
between the 181Leu allele and measures of atopy in
a small random sample of 13 subjects.50 Similarly, in a
set of unrelated nuclear families with allergic asthmatic
probands, strong association with atopy was found with a
maternal pattern of inheritance.50 The 181Leu/183Leu
allele was found at high frequency (72%) in Kuwaiti Arabs
and was associated with asthma.51 In a study of South
African blacks and whites, 181Leu was detected at a high
frequency52 and an association of 181Leu in white South
African asthmatics was seen.50
A third coding polymorphism in the FCERB1 gene,
called Glu237Gly, has been found at a low frequency
(5%) in a number of populations.48,49 In Caucasians, sig-
nificant associations between 237Gly with BHR and skin
test responses to grass and house dust-mite allergies
have been reported.48 The 237Gly allele occurs at a high
frequency in Japanese asthmatics (20%)49 and is associ-
ated with atopic asthma, in particular, childhood asthma,
as well as with high total serum IgE levels.50
Two additional polymorphisms that alter the amino
acid sequence of the protein have also been identified
within these genes (Rsal_in253 and RsaI_ex754). They
have shown strong associations with atopic eczema and
asthma in a study of families recruited through a child
affected with eczema.55,56 Therefore, a number of studies
implicate the FCERB1 gene as having an influence on the
pathogenesis of allergic disease.50
The second locus for asthma on 11q13.1 is close to
D11S480/D11S1883, approximately 5 cM telomeric
to FcεRIβ.50 Strong linkage with clinical symptoms (e.g.
asthma) at D11S480 in 40 British asthmatic families has
been found (M Dubowitz et al., unpubl. data, 1995).50
Recently, a strong genetic association was found between
childhood asthma and CC16,57 1 cM centrometric to
D11S480 on 11q13.1. The gene for Clara cell secretary
protein, CC16, is a plausible candidate because of
its involvement in the control of airway inflammation.50
Protein studies have revealed significant differences in
levels of CC16 between asthmatics and healthy con-
trols.50 Another candidate is CHRM1,58 a muscarinic
receptor on airways; however, no association was found
in our population.42 A third atopic asthma locus on
11q13.1 has been reported telomeric to FGF3, more
than 10–12 cM away from FcεRIβ. Genetic linkage or
association for atopic asthma has been found on 11q13.1
with other markers, including FGF3,59 D11S53460 or
D11S97,61 in relation to total serum IgE levels, or
D11S52760 in relation to asthma or BHR.
CONCLUDING REMARKS
We have provided evidence that human genetic varia-
tion and exposure to certain infections in early childhood
are key influences of allergy. The overall picture emerg-
ing from the genetic and functional analyses provides
increasing evidence that there are major loci for asthma
and atopy in relation to signaling of IL-4 and IL-13
through IL-4Rα–STAT6. Interleukin-4Rα and STAT6 are
essential for the action of both cytokines and for the
development of asthma and atopy. These findings are of
immediate importance in the planning of new drug
therapies (personalized medicine) in atopic disorders.
It is clear that the recent rapid rise in atopic disorders
has been in certain environments, where exposure to
infection has fallen swiftly due to improved hygiene. In a
large population of Japanese children from Wakayama,
exposure to the tuberculosis microorganism in early life
very strongly predicts less asthma and atopy in later child-
hood. It was proposed that such infections in early life
program the immune system in a way that is antagonistic
to the development of atopic disorders. There is some
evidence from other researchers that confirms that tuber-
culosis organisms may prevent experimental allergy in
mice. These findings lay the foundation for developing
vaccines that mimic the exposure to tuberculosis and that
need to be trialled for preventing asthma and atopy.
There is an urgent need for a more fundamental under-
standing of the origins of allergy in order to plan more
effective treatment and prevention.
Allergy is multifactorial disease affected by interacting
genetic and environmental factors. However, it remains
unknown how environmental and relevant variants inter-
act. Thus, it is necessary to develop a model to analyze
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the relationships between the complicated genetics and
to develop a ‘model’ to clarify the effects of environ-
mental factors.
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